These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10509530)

  • 1. CYP2C9*3 allelic variant and bleeding complications.
    Ogg MS; Brennan P; Meade T; Humphries SE
    Lancet; 1999 Sep; 354(9184):1124. PubMed ID: 10509530
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
    Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
    Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic control of anticoagulation.
    Mannucci PM
    Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
    [No Abstract]   [Full Text] [Related]  

  • 5. Warfarin dose requirement and CYP2C9 polymorphisms.
    Halkin H; Lubetsky A
    Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
    [No Abstract]   [Full Text] [Related]  

  • 6. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
    Ablin J; Cabili S; Lagziel A; Peretz H
    Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9 polymorphism and warfarin dose requirements.
    Daly AK; Day CP; Aithal GP
    Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 10. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
    Rettie AE; Wienkers LC; Gonzalez FJ; Trager WF; Korzekwa KR
    Pharmacogenetics; 1994 Feb; 4(1):39-42. PubMed ID: 8004131
    [No Abstract]   [Full Text] [Related]  

  • 11. Major bleeding caused by warfarin in a genetically susceptible patient.
    Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
    Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the CYP2C9 gene and the response to warfarin.
    Yasar U; Oscarson M; Eliasson E; Sjöqvist F
    Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M; Brancaccio V; Ciampa A; Di Minno G
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
    Taube J; Halsall D; Baglin T
    Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.
    Goldstein JA
    Br J Clin Pharmacol; 2002 Apr; 53(4):409-10. PubMed ID: 11966681
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
    Yasar U; Eliasson E; Dahl ML
    Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
    [No Abstract]   [Full Text] [Related]  

  • 17. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
    Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
    Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
    Redman AR
    Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.